QPS is a GLP/GCP-compliant CRO supporting discovery, preclinical and clinical drug development. We provide quality services to clients worldwide. Our core competencies are neuropharmacology, drug metabolism pharmacokinetics (DMPK), toxicology, bioanalysis, biomarkers, early and late phase clinical research. We have laboratories and clinics located in the United States, Europe, and Asia/Pacific.

QPS has expanded service and capacity within our Translational Medicine (TLM) group in DE. In addition to PK ligand binding, rt/d/dd/q-PCR, immunogenicity (ADA and nAb—cell based and ligand), and biomarkers, we have added Flow Cytometry Q3, 2024. Our LC-MS/MS group has added a specialized team for large molecule bioanalysis via hybrid-LC/MS/MS and HRMS.

Our bioanalytical site in the Netherlands offers LC-MS/MS and ICP-MS services. We have added an expanded TLM group to mirror the offerings of the Delaware site.

DMPK specializes in QWBA studies.

🔗 http://qps.com

CONNECT:

Mark Warren
Director, Business Development
📧 mark.warren@qps.com
📞 650.769.0002
3 Innovation Way, Suite 240
Newark, Delaware 19711